Results 21 to 30 of about 108,162 (269)

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-Cλ interface

mAbs, 2023
Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities.
John D. Bagert, Vaheh Oganesyan, Chi-I Chiang, Mike Iannotti, Jia Lin, Chunning Yang, Sterling Payne, Will McMahon, Samuel Edwards, Andrew Dippel, Mark Hutchinson, Fengying Huang, Vineela Aleti, Chendi Niu, Chen Qian, Jessica Denham, Sofia Ferreira, Pallab Pradhan, Mark Penney, Chunlei Wang, Wenhai Liu, Even Walseng, Yariv Mazor   +22 more
doaj   +1 more source

Engineered Fc-glycosylation switch to eliminate antibody effector function

mAbs, 2020
Antibodies mediate effector functions through Fcγ receptor (FcγR) interactions and complement activation, causing cytokine release, degranulation, phagocytosis, and cell death. They are often undesired for development of therapeutic antibodies where only
Qun Zhou, Julie Jaworski, Yanfeng Zhou, Delphine Valente, Joanne Cotton, Denise Honey, Ekaterina Boudanova, Jochen Beninga, Ercole Rao, Ronnie Wei, Christine Mauriac, Clark Pan, Anna Park, Huawei Qiu   +13 more
doaj   +1 more source

Comprehensive modeling of cell culture profile using Raman spectroscopy and machine learning

Scientific Reports, 2023
Chinese hamster ovary (CHO) cells are widely utilized in the production of antibody drugs. To ensure the production of large quantities of antibodies that meet the required specifications, it is crucial to monitor and control the levels of metabolites ...
Hiroki Tanemura, Ryunosuke Kitamura, Yasuko Yamada, Masato Hoshino, Hirofumi Kakihara, Koichi Nonaka   +5 more
doaj   +1 more source

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

Journal for ImmunoTherapy of Cancer, 2022
Background Cancer immunotherapy has revolutionized cancer treatment. However, considering the limited success of immunotherapy to only some cancer types and patient cohorts, there is an unmet need for developing new treatments that will result in higher ...
Frank Nestle, Ilana Mandel, Dana Haves Ziv, Ilana Goldshtein, Tsuri Peretz, Dror Alishekevitz, Anna Fridman Dror, Motti Hakim, Sharon Hashmueli, Itay Friedman, Yair Sapir, Rita Greco, Hongjing Qu, Dmitri Wiederschain, Lily Pao, Sharad Sharma, Tehila Ben Moshe   +16 more
doaj   +1 more source

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Nature Communications, 2022
Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D.
Hongwei Jiang, Shuguang Pang, Yawei Zhang, Ting Yu, Meng Liu, Huan Deng, Li Li, Liqi Feng, Baili Song, Han Han-Zhang, Qingyang Ma, Lei Qian, Wenying Yang   +12 more
doaj   +1 more source

Engineering an anti-CD52 antibody for enhanced deamidation stability

mAbs, 2019
Deamidation evaluation and mitigation is an important aspect of therapeutic antibody developability assessment. We investigated the structure and function of the Asn-Gly deamidation in a human anti-CD52 IgG1 antibody light chain complementarity ...
Huawei Qiu, Ronnie Wei, Julie Jaworski, Ekaterina Boudanova, Heather Hughes, Scott VanPatten, Anders Lund, Jaime Day, Yanfeng Zhou, Tracey McSherry, Clark Q. Pan, Rebecca Sendak   +11 more
doaj   +1 more source

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

EClinicalMedicine, 2021
Background: IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.
Linong Ji, Hongwei Jiang, Pei An, Huan Deng, Meng Liu, Li Li, Liqi Feng, Baili Song, Han Han-Zhang, Qingyang Ma, Lei Qian   +10 more
doaj   +1 more source

A potential new biological marker of the biological age [PDF]

Frontiers in Genetics, 2013
For many years, data have been accumulated which point to a significant similarity between the nature of the brain damage in the aging process (in the case of dementia or even in outwardly healthy elderly people) and the brain damage caused by prion diseases of humans and animals (Sobel, 1970; Fraser and McBride, 1985; Masters et al., 1985; Gajdusek ...
Zuev, Victor A., Mezentseva, Marina V., Schaposchnikova, Galina M.   +2 more
openaire   +3 more sources

Targeted Delivery of Exosomes Armed with Anti-Cancer Therapeutics

Membranes, 2022
Among extracellular vesicles, exosomes have gained great attention for their role as therapeutic vehicles for delivering various active pharmaceutical ingredients (APIs).
Hojun Choi, Hwayoung Yim, Cheolhyoung Park, So-Hee Ahn, Yura Ahn, Areum Lee, Heekyoung Yang, Chulhee Choi   +7 more
doaj   +1 more source

On Biological Nomenclature.: [PDF]

Science, 1892
n ...
openaire   +2 more sources